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ABSTRACT
A growing number of jurisdictions now request economic data in
support of their decision-making procedures for the pricing and/or reim-
bursement of health technologies. Because more jurisdictions request
economic data, the burden on study sponsors and researchers increases.
There are many reasons why the cost-effectiveness of health technologies
might vary from place to place. Therefore, this report of an ISPOR
Good Practices Task Force reviews what national guidelines for
economic evaluation say about transferability, discusses which elements
of data could potentially vary from place to place, and recommends
good research practices for dealing with aspects of transferability, includ-
ing strategies based on the analysis of individual patient data and based
on decision-analytic modeling.
Keywords: cost-effectiveness analysis, decision-analytic models, economic
clinical trials, resource allocation.
Background to theTask Force
In December 2004, the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) Health Science Policy
Council recommended that the issue “Transferability of Eco-
nomic Data: When Does a Difference Make a Difference?” be
considered by the Board of Directors. The Council’s recommen-
dations concerning transferability of economic data were as
follows: deﬁne key variable economic data and deﬁne guidelines
for acceptance data from outside a country, taking into consid-
eration existing national guidelines. After further development of
the issue by the Health Science Policy Council, the Board
approved the creation of a Task Force on Good Research Prac-
tices on Transferability of Economic Data in Health Technology
Assessment in May 2005 and advised that the Task Force be
under the leadership of the Health Science Policy Council. Task
Force leadership and reviewer groups were ﬁnalized by Decem-
ber 2005.
Task Force members were experienced in health economics
and technology assessment and were drawn from both industry
and academia. In addition, several members had experience in
working with reimbursement agencies in their respective coun-
tries. The members came from Italy, The Netherlands, Poland,
Switzerland, the United Kingdom, and the United States.
Beginning in May 2006, the Task Force conducted monthly
and bimonthly teleconferences to develop core assumptions and
an outline before preparing a draft report. A face-to-face meeting
was held in January 2005 to develop consensus for the draft ﬁnal
report. The draft ﬁnal report was posted on ISPOR’s Web site
in April 2008, and the task force’s reviewer group and ISPOR
general membership were invited to submit their comments for
a 1-month review period. In total, 50 individuals or groups
responded. All comments received were posted on the ISPOR
Web site and presented for discussion at the Task Force Forum at
ISPOR’s 13th Annual International Meeting in May 2008. Com-
ments and feedback from the forum were considered and, when
appropriate, incorporated and acknowledged in the ﬁnal report.
Introduction
A growing number of jurisdictions now request economic data in
support of their decision-making procedures for the pricing
and/or reimbursement of health technologies. In most cases, the
requests for data are supported by national guidelines on the
conduct of economic evaluation [1,2]. Because more jurisdictions
request economic data, the burden on study sponsors and
researchers increases, especially as the various national guidelines
may insist on the presentation of local data or the use of speciﬁc
methods.
There are many reasons why the cost-effectiveness of health
technologies might vary from place to place, including the inci-
dence and severity of the disease in question, the availability
of health care resources, clinical practice patterns, and relative
prices [3]. The extent of variation in estimates has been shown in
a review of economic evaluations of medicines undertaken in
Western Europe [4]. It was found that, in 17 out of 27 cases, the
variation in the estimates of the incremental cost-effectiveness
ratios could be considered to be substantial (a twofold difference
likely to change the decision to reimburse the drug). Therefore,
it is reasonable for national guidelines to request that analyses
be relevant to the local context.
Nevertheless, the requirement that economic evaluations
should use local data or that particular methods should be
used means that analyses increasingly need to be customized for
each setting. Therefore, the objectives of the Task Force were 1)
to review what national guidelines for economic evaluation say
about transferability; 2) to discuss which elements of data could
potentially vary from setting to setting; and 3) to recommend
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good research practices for dealing with aspects of transferability
(including analytic strategies and guidance for considering the
appropriateness of evidence from other countries).
The Task Force’s working deﬁnitions were that economic
evaluations were generalizable if they applied, without adjust-
ment, to other settings. On the other hand, data were transfer-
able if they could be adapted to apply to other settings. Also, the
generic term “jurisdiction” was used to mean any setting where
there is a need for local estimates of cost-effectiveness. Often, this
would be a country but could also be a region within a country
or a particular payer, such as a health plan. Nevertheless, when
referring to a particular study, more speciﬁc terms like “country”
and “clinical center” are used if they help in the explanation of
the study’s methods.
Finally, the Task Force’s work focused on the transferabi-
lity of the data and analyses used to produce local estimates of
cost-effectiveness. It was not within the remit to discuss the
transferability of decision-making criteria, such as the threshold
value of the incremental cost-effectiveness ratio (ICER) deemed
to be “acceptable” in different jurisdictions.
Variations in Current Guidance on the
Transferability of Economic and Clinical
Data for Economic Evaluation
The full results of our review of existing national methods guide-
lines are published elsewhere [5] but are summarized here. All the
guidelines recognize that there are several issues relating to the
transferability of economic data but differ in the extent to which
they discuss these in detail. There is also considerable variation in
the methods for addressing transferability, not all of which can be
justiﬁed.
Most guidelines (16 out of 21 reviewed) recognize the poten-
tial for differences in the clinical parameters from one country to
another, and these can lead to differences in cost-effectiveness.
The majority of guidelines suggest that jurisdiction-speciﬁc esti-
mates of baseline risk should be used in cost-effectiveness studies
and that treatment effect (i.e., relative risk reduction) from clini-
cal trials might be more generalizable across settings. Neverthe-
less, there is not unanimous agreement on this, and a small
number of guidelines do not make a distinction between relative
and absolute risk reduction.
Less than 40% of the guidelines (8 out of 21) make any
recommendations about the transferability of health state valu-
ations or utility estimates between jurisdictions. The remaining
guidelines recommend the use of utility values from the jurisdic-
tion of interest or at least values that are applicable to the
jurisdiction of interest. One set of guidelines [4] even speciﬁes the
method by which the utility estimates should be obtained, sug-
gesting that a generic instrument is preferred.
Most guidelines recommend that resource quantities should
be reported separately from unit costs (prices) to increase the
transparency of the analysis. All the guidelines agree that unit
cost prices should be jurisdiction speciﬁc because of differences in
relative or absolute price levels among jurisdictions. Some guide-
lines also provide sources for unit costs (e.g., an ofﬁcial list).
Almost all guidelines require that data on resource use should be
from or adapted to the jurisdiction of interest. Nevertheless,
there is no consistent guidance on how such data should be
obtained (e.g., from trials or from local databases) or on how any
adjustments should be made.
Therefore, it does appear that the various methods guidelines
differ sufﬁciently in their requirements and those issues of eco-
nomic data transferability need to be addressed.
Developing Good Research Practices for
Dealing with Aspects of Transferability
Overview of Possible Strategies
The approach for dealing with aspects of transferability is likely
to depend on two key factors: the decision-maker’s requirements
and data availability. Many economic evaluations published in
the literature have been performed with no speciﬁc decision-
maker in mind. In such cases, the approach for dealing with
aspects of transferability is based entirely on data availability and
the attributes of the various analytic methods.
Nevertheless, the main focus of this report is on those situa-
tions where a particular decision-maker can be speciﬁed. Here,
the decision-maker’s requirements may also help determine the
analytic approach. For example, in choosing comparators for a
given evaluation in England and Wales, the National Institute for
Health and Clinical Excellence [6] states that “all relevant alter-
natives should be compared.” This means that an analysis based
on a single trial would be unlikely to be sufﬁcient, unless the trial
compared all the relevant treatment options. Therefore, an
approach based on modeling is likely to be preferred. On the
other hand, in The Netherlands, the guidelines for pharmacoeco-
nomics [7] stipulate that the comparator should be the standard
treatment as is mentioned in practice guidelines and for which
effectiveness is demonstrated, and, in Germany, the Institute for
Quality and Efﬁciency in Health Care favors estimates of effec-
tiveness obtained directly from clinical trials. Therefore, in
Germany in particular, decision-makers are more likely to favor
an approach based on the analysis of individual patient data
from one or more randomized controlled trials rather than a
modeling approach involving a synthesis of estimates from a
range of sources [8].
The availability of data is another important factor determin-
ing transferability of cost-effectiveness results. Manca and Willan
[9] have proposed an algorithm based on the availability of data.
For example, if the jurisdiction of interest has participated in a
multinational clinical trial in which data on resource use and/or
cost have been collected, the preferred strategy would be to
analyze the individual patient data from that trial. If this were
not the case, a modeling approach would usually be required,
using as much clinical, resource use, and cost data as possible
from the jurisdiction of interest. This report takes the argument
further and considers analytic strategies based on the analysis of
individual patient data gathered in clinical trials, and strategies
based on decision-analytic modeling. The various strategies are
initially discussed separately, but, later in the article, the synergies
between them are also explored.
Deﬁning the decision problem. For any evaluation, it is impera-
tive to have a clear and appropriately speciﬁed decision problem
deﬁned in advance. In the context of decisions about a new
technology, this would require a statement of the patient popu-
lation and subpopulations of interest and the comparators to the
new technology. In this context, “comparator” will be a thera-
peutic option or strategy that could be used instead of the new
technology. It is quite feasible for an appropriately speciﬁed
decision problem to include a large number of alternative
options.
It is possible that an appropriately speciﬁed decision problem
relating to a new technology would vary between jurisdictions.
One reason, in the case of pharmaceuticals, is that licenses can
differ between jurisdictions, and this can affect the clinical appli-
cations of the new product or those of the comparators. A second
reason relates to differences in routine clinical practice, where
health technologies used in one jurisdiction are simply not used
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in another, and this can affect the choice of comparators. Differ-
ences in clinical practice may also inﬂuence the speciﬁcation of
treatment strategies. For example, in deﬁning appropriate com-
parators for aspirin plus clopidogrel in the management of acute
coronary syndrome, it may be appropriate to specify aspirin as
the only alternative in the United Kingdom, but, in Italy, it may
be considered appropriate also to include ticlopidine. It should
be noted, however, that just because particular health technolo-
gies are not currently used in a particular jurisdiction does not
mean they should never be used, and a completely speciﬁed
decision problem may include such options to fully inform
decision-making.
To guide the reader through this report, we propose four steps
that consider data availability and determine whether simple or
more elaborate methods for adjusting cost-effectiveness informa-
tion to a particular jurisdiction are needed. These four steps are
outlined in Figure 1. First, in some situations, a cost-effectiveness
study may already exist for another jurisdiction but generally will
not be directly applicable to the jurisdiction of interest. There-
fore, before considering developing a new economic evaluation
for the jurisdiction of interest, it will be useful for the analyst to
assess whether the results of the existing study can be adapted
to make them transferable. Therefore, the question arises as to
whether cost-effectiveness estimates can be transferred to another
speciﬁed jurisdiction and, if not, what adjustments of these esti-
mates or even the cost-effectiveness study are possible and/or
necessary?
It is possible to identify two situations where cost-
effectiveness estimates for another jurisdiction are available and
where the level of transferability could be assessed:
1. The cost-effectiveness results are not transferable because the
starting points of the study are irrelevant to the decision-
maker. If either the experimental technology or the compara-
tor(s) is (are) not relevant in the jurisdiction of interest, the
cost-effectiveness results are irrelevant. Additionally, if
the methodological quality of the cost-effectiveness study
does not meet the local standards, transfer of the cost-
effectiveness estimate is not valid. These aspects are so-called
“general knockout criteria” (i.e., factors that preclude trans-
ferability) [10]. Furthermore, the patient population that is
relevant to the use of the health-care technology may be
different between jurisdictions and, therefore, the cost-
effectiveness information is not transferable.
2. The cost-effectiveness results are only transferable after
adjustment for differences in treatment patterns, in unit
costs, or other aspects For instance, the setting where a
patient is treated (e.g., in a hospital or by family physicians)
can differ between jurisdictions, and this can make a differ-
ence to the results. Therefore, practice variations between
jurisdictions may make the transferability of cost-
effectiveness estimates impossible without adjustment [10].
Furthermore, differences in unit costs between jurisdictions
make recalculation necessary, and, for this reason, either
jurisdiction-speciﬁc cost data might be required or a more
simple adjustment may be made, for instance, based on
purchasing power parities [10]. Also, the deﬁnition of the
time horizon of the analysis may be important because the
prerequisites for this might differ between jurisdictions.
Other characteristics of existing cost-effectiveness informa-
tion, for which adjustment may be required, concern the
perspective used and the impact this has on the approach
for estimating health care costs (e.g., charges, fees, real
costs), the discount rates applied, and whether productivity
or time costs are included and how they are valued (e.g.,
human capital or friction cost method). These are called
“speciﬁc knockout criteria” (i.e., aspects of the analysis that
would have to be addressed before transfer of estimates is
possible) [10].
If, from the answers to the questions in the ﬁrst three steps in
Figure 1, it becomes clear that the available cost-effectiveness
information is not directly transferable through a simple adjust-
ment procedure, Step 4 indicates that there are two options.
If patient data from multilocation studies are available includ-
ing the jurisdiction of interest, there are analytic techniques to
Figure 1 Steps for determining appropriate
methods for adjusting cost-effectiveness (CE)
information.
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calculate adjusted cost-effectiveness estimates for the jurisdiction.
These methods differ in level of sophistication. Nevertheless, if
the trial was undertaken wholly outside the jurisdiction of inter-
est, the transferability issues will usually be addressed through
parameterization of a decision-analytic model, although it may
be possible to make some inferences from the adjusted cost-
effectiveness estimates for jurisdictions that did participate in the
trial, particularly if one or more of them was thought to be
similar to the jurisdiction of interest.
Analyzing Individual Patient Data from
Multilocation Studies
Most large clinical trials enrol patients from several jurisdictions.
When data on resource use (and/or cost and/or utilities) are
gathered alongside the trial, the analysis of individual patient
data can be the basis for exploring issues of economic data
transferability.
Analytic methods to address the many complexities inherent
in multilocation studies have rapidly evolved in recent years. In
this section, the current literature is summarized, identifying the
advantages and limitations of various approaches to addressing
issues of transferability, and making recommendations about
which approaches should be avoided and which should be con-
sidered for application. Several areas where there are likely to be
further methodological advances are also identiﬁed.
With regard to transferability, analytic approaches address
two sets of objectives. The ﬁrst is to evaluate whether there is
evidence of heterogeneity in patterns of resource use, costs, sur-
vival, and/or utilities exist among jurisdictions included in the
trial and to explore potential sources of heterogeneity. The
second objective is to obtain estimates of incremental resource
use, cost, and/or cost-effectiveness that are appropriate for
decision-making within particular jurisdictions that may or may
not have been included in the trial. Analytic methods for both
objectives will vary depending on the types of data available to
the analyst. An algorithm developed by Manca and Willan[9]
differentiates strategies according to whether the trial enrolled
patients from the jurisdiction of interest and whether individual
patient-level data (IPD) from the trial are available to the analyst.
In this section, we assume the analyst has access to patient-level
data from the multilocation trial.
Three general statistical methods comprise the literature:
1) detection of heterogeneity; 2) ﬁxed effects models; and 3)
multilevel or hierarchical models.
Detection of heterogeneity. A prerequisite step in identifying
presence of heterogeneity before statistical modeling is the
examination of descriptive statistics to identify key differences
between jurisdictions in incremental costs and effects. In many
cases, it may be necessary to group patients across jurisdictions
with small sample sizes to avoid jeopardizing patient conﬁden-
tiality. Exploration of potential heterogeneity using point esti-
mates and conﬁdence intervals is encouraged but should not
represent the sole basis for conclusions about similarities or
differences between jurisdictions.
The identiﬁcation of heterogeneity in economic measures
(e.g., incremental resource use, cost, and cost-effectiveness)
across jurisdictions participating in a multilocation trial can be
handled in the same statistical manner as the identiﬁcation of
heterogeneity in the clinical measures from the trial [11]. One
approach involves tests of qualitative and quantitative interac-
tions developed by Gail and Simon [12]. A quantitative interac-
tion represents a situation where the direction of the treatment
effect is consistent but not the magnitude (i.e., treatment
decreases resource use in all jurisdictions but to a greater extent
in some and to a lesser extent in others); a qualitative interaction
represents a situation where the direction of the treatment effect
is different (i.e., treatment increases resource use in some juris-
dictions and decreases resource use in others) (Fig. 2) [12].
Although these tests can be applied separately to a health
technology’s impact on resource utilization, costs, and effects,
results from separate tests do not necessarily provide insight as to
whether jurisdictions differ (in either direction or magnitude)
with respect to cost-effectiveness. Instead, the appropriate appli-
cation for cost-effectiveness analysis is to employ the statistical
tests directly on the incremental net beneﬁts (health or monetary)
or cost-effectiveness ratio. If there is no evidence of heterogeneity
and if the test is powerful enough to rule out economically
meaningful differences, it is recommended that the pooled or
ﬁxed treatment effect across all jurisdictions be used to summa-
rize the study’s results. Nevertheless, if the test reveals evidence
of heterogeneity, a pooled estimate of cost-effectiveness should
not be used to represent the trial-wide results and, thus, is not
transferable across jurisdictions.
There are two main disadvantages of this approach. One is
that tests of homogeneity are typically underpowered, especially
when relatively small numbers of patients are enrolled in indi-
vidual jurisdictions. This limitation can be partially addressed
by combining patients from jurisdictions with similar practice
characteristics (e.g., types of facilities and providers or charac-
teristics of reimbursement systems). Unless there is a theoretical
basis for pooling jurisdictions, there is no empirical basis about
how such pooling should be accomplished. Ex post, one might
pool jurisdictions with the most similar results in an attempt to
maximize the opportunity to identify any evidence of heteroge-
neity that may exist. Limited power can also be addressed by
using larger a levels (e.g., 0.1 or 0.2). An additional disadvan-
tage to this approach is that it can only be used to evaluate
whether there is evidence of heterogeneity; it does not offer a
natural extension to generate jurisdiction-speciﬁc estimates of
cost-effectiveness.
Figure 2 Representation of qualitative and quan-
titative interactions by Gail and Simon [12].
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Fixed effect models. The simplest way analysts have accounted
for potential differences among jurisdictions has been to include
a set of ﬁxed effects for jurisdictions that participated in the trial.
Nevertheless, the inclusion of these ﬁxed effects was typically to
“control for” differences across jurisdictions rather than to
explore evidence of heterogeneity or to produce jurisdiction-
speciﬁc results. Thus, this approach is not adequate for address-
ing the transferability issue that is the focus of this article.
Willke et al.[13] extended the use of ﬁxed effects models to
separate the direct effect of a study treatment on costs, to include
changes in resource use independent of the patient’s clinical
outcome and the indirect effect of a study treatment on costs
through changes in the patient’s clinical status. Through the use
of multiple treatment-by-country and country-by-outcome inter-
action terms, the approach estimates country-speciﬁc direct and
indirect effects of study treatment on costs. The advantage of this
approach is that it uses patient-level data and standard statistical
procedures to estimate country-speciﬁc differences of both costs
and effects. It also enables sensitivity analyses, particularly with
respect to country-speciﬁc treatment outcomes.
Koopmanschap et al. [14] also applied a regression approach
to adjust estimates of resource use for differences observed
across countries and evaluated costs as though all patients were
enrolled from a single country. Although these regression-based
approaches may be more familiar to most analysts, the applica-
tion of ﬁxed effect regression models does not account for the
inherently hierarchical data structure in multilocation clinical
trials. Failure to incorporate the clustering that can exist within
each jurisdiction will result in an overestimation of precision,
leading to conﬁdence intervals that are too narrow.
Multilevel models. Most of the recent literature has focused on
the application of multilevel (or hierarchical or random effects)
models to economic information (i.e., costs, effectiveness, incre-
mental net beneﬁt, and the incremental cost-effectiveness ratio)
derived from multilocation trials [15–22]. These models may
not be necessary when just a few jurisdictions (i.e., less than 4
or 5) are represented in the trial. Nevertheless, one of their
advantages over ﬁxed effects models and tests for detecting het-
erogeneity is that they can appropriately handle the hierarchical
nature of the data that manifests itself as a lack of indepen-
dence of the errors between the observations. This hierarchical
structure occurs because of within-jurisdiction similarities
in clinical practice patterns, price weights for health-care
resources, lifestyle and health behaviors [23], and other factors.
When used to analyze data from multilocation studies involving
study sites in several jurisdictions, these models also allow
lower level clustering (e.g., study sites or clinical centers, phy-
sicians), as well as heterogeneity in treatment effect across
countries, to be incorporated in the analysis. By extension, they
provide a formal means of estimating jurisdiction-speciﬁc mea-
sures of cost-effectiveness through the calculation of random
intercepts and random slopes, also described as empirical Baye-
sian shrinkage estimation [19].
By borrowing information from the pooled estimates, shrink-
age estimation yields smaller standard errors for jurisdiction-
speciﬁc measures of costs and cost-effectiveness relative to the
standard errors derived from each jurisdiction’s data alone
[19–21]. Each jurisdiction’s estimate of costs or cost-effectiveness
is also shrunken toward the summary estimate by “borrowing
strength from across jurisdictions” [20]. The extent to which this
shrinkage affects each jurisdiction’s estimate is dependent on the
variability among the jurisdiction-speciﬁc estimates in the trial
(more between-jurisdiction variability, less shrinkage), the vari-
ability within a jurisdiction (more within-jurisdiction variability,
more shrinkage), and the number of trial participants from the
jurisdiction (more participants, less shrinkage) [15].
The impact of within versus between variability and the
number of patients on the degree of shrinkage have a direct
parallel to the statistical assessment of heterogeneity and the
use of the pooled or ﬁxed effect estimate. The greater within-
jurisdiction variability relative to the between-jurisdiction vari-
ability, the greater shrinkage and the lower the likelihood that
one will detect heterogeneity. Without evidence of heterogeneity,
the pooled effect may be used to represent the study’s results.
Conversely, the greater the number of trial participants, the less
the shrinkage and the greater the power to detect heterogeneity.
With evidence of heterogeneity, ﬁxed effects or shrunken
estimates may be preferred for reporting the study’s results. In
essence, the pooled estimates can be viewed as fully shrunk, and
the ﬁxed effect estimates can be viewed as not shrunk toward the
summary measure. Shrinkage estimation allows for a partial shift
toward the pooled estimate rather than assuming it is all or
nothing.
Multilevel models can also be used to derive a pooled,
random effects estimate across all jurisdictions, equivalent to a
random effects summary estimate from meta-analysis [19,21].
When applying multilevel models, analysts must make two sets
of assumptions. One pertains to the estimates at the level of
an individual jurisdiction, and one pertains to the collection of
jurisdiction-speciﬁc estimates. At the country level, most analysts
have assumed a normal distribution with a mean and variance
speciﬁc to each country [19]. Others have extended the models
by employing gamma distributions and multiplicative effects, and
have shown that these speciﬁcations are preferable for cost data
[22]. In regard to the collection of country-speciﬁc, random
effects estimates, most applications of multilevel models have
been based on the assumptions that the parameters are drawn
from a common distribution, or are “exchangeable,” and are
represented by a common variance across all countries. The term
“exchangeable” means that there are no other a priori reasons
why one jurisdiction may have more or less favorable measures
of costs or cost-effectiveness than another [24]. Making an a
priori assumption that one does not expect differences in
jurisdiction-speciﬁc measures of cost-effectiveness may be unrea-
sonable when the question we are trying to answer is whether
or not such differences exist.
Some authors have tried to overcome this problem by includ-
ing center-level and/or country-level covariates, thought to cor-
relate with measures of costs or cost-effectiveness, which allows
one to make an assumption about exchangeability through con-
ditional independence [25]. For example, the inclusion of these
higher-level covariates that are thought to distinguish between
centers or countries with worse or better measures of cost or
cost-effectiveness allows for shrinkage toward two (or more)
separate pooled (i.e., local) means. Currently, evidence is lacking
as to what types of higher-level covariates may be useful in this
regard, but candidate variables may include those that are indica-
tive of macroeconomic characteristics (e.g., gross national
product), capacity constraints (e.g., limited availability of inten-
sive care beds), economic incentives (e.g., pressure to minimize
length of stay), or ﬁnancing characteristics (e.g., global budgets
vs. fee-for-service reimbursement) associated with various prac-
tice sites or health systems. There is also little agreement about
tests that should be used to evaluate the appropriateness of
shrinkage toward one, two, or more such local means. Finally,
the inclusion of higher-level variables also allows estimation of
cost-effectiveness for centers or countries that did not participate
in the trial. This approach assumes that the analyst has identiﬁed
Economic Evaluations across Jurisdictions 413
the appropriate set of higher-level covariates for the exchange-
ability assumption to hold and that the characteristics of the
country of interest are represented appropriately by countries
participating in the trial.
Displaying the results. Findings from ﬁxed effect, pooled effect,
and random effects can be displayed as forest plots. To illustrate
this, we reproduce two forest plots based on an analysis of the
ATLAS trial [21]. The forest plot on the left-hand side of Figure 3
represents the ﬁxed effects (means and conﬁdence intervals) for
individual countries and the pooled effect across the 17 countries
participating in the trial. The plot on the right-hand side repre-
sents the shrunken estimates for each of the countries along with
a pooled, random effects estimate across all countries, equivalent
to a random effects summary estimate from a meta-analysis. As
expected, countries shrink more toward the pooled estimate if
they have the following: 1) greater variability in the ﬁxed effects
analysis (as identiﬁed by the width of the conﬁdence interval);
or 2) smaller sample sizes (as identiﬁed by the relative size of the
box for the point estimate).
The application of multilevel modeling to data from multilo-
cation studies is continuing to evolve [21,26]. Therefore, it would
be premature to comment on best practices or on situations
where multilevel modeling may or may not be advantageous over
simpler analytic approaches.
Summary. Where IPD are available, all three of these methods
can be used to identify heterogeneous treatment effects on
measures of cost and cost-effectiveness across jurisdictions.
Nevertheless, they vary in regard to their utility in exploring
jurisdiction-level and patient-level variables that may be associ-
ated with heterogeneity. With regard to developing jurisdiction-
speciﬁc estimates, the ﬁxed effect model and the multilevel
models have the advantage that such estimates are natural exten-
sions of these analytic frameworks. Nevertheless, each of these
approaches assumes that patient-level estimates of cost and effect
are measured quantities. In the majority of cost-effectiveness
analyses, particularly those that take a lifetime perspective, these
quantities are estimated through some type of modeling process.
Thus, these approaches may not be directly applicable. In the
future, we may expect to see further methodological advances
aimed at adapting the multilevel modeling framework to other
analytic strategies to extrapolate estimates beyond the trial
period [9].
Addressing Transferability Issues in
Decision-Analytic Models
Introduction. Decision-analytic models are increasingly being
used as vehicles for economic evaluation. One of the key features
of decision models is that they provide a framework within
which evidence from a range of sources can be assembled. This
could, for example, relate to treatment effectiveness data from
a meta-analysis of international trials, resource use data from
a single observational data, unit costs from a particular jurisdic-
tion, and utility data from a range of published sources.
When considering undertaking a cost-effectiveness analysis to
inform decision-making in a particular jurisdiction, there are a
number of situations where decision-analytic modeling might be
considered to be the preferred basis for cost-effectiveness analysis
[27–28] including:
1. when the available trials were undertaken wholly outside
the jurisdiction of interest and one or more components
of evidence cannot be considered generalizable to that
jurisdiction;
2. when there is more than one relevant source of evidence
relating to any aspect of the analysis—e.g., treatment effect,
baseline risks, resource use, or quality of life (QoL);
3. where a trial exists, but some other aspect of the economic
evaluation is not consistent with the design of that trial.
Obvious examples would be that the period of follow-up
in the trial is not the same because the appropriate time
horizon for the economic analysis or the options being
compared in the trial represent only a subset of those con-
sidered relevant in the country of interest; and
4. a decision model has been developed (using a range of
evidence sources) for another jurisdiction and might be
adapted to support decision-making in another.
Figure 3 “Pooling” and “splitting” (left) vs. hierarchical modeling (right) for multinational trials: estimating country-speciﬁc mean difference in cost. The black circle
indicates the trial-wide estimate.The square markers indicate the country-level mean estimates of differential costs.The size of the markers is proportional to the
sample of patients recruited in each country. Finally, the horizontal bars represent the 95% conﬁdence intervals.
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Determining model structure. A model’s structure relates to how
it speciﬁes the natural history of a disease and the effects of a set
of interventions. Depending on the type of model selected (e.g., a
state transition model or a decision tree), the structure embodies
the choice of states/pathways and how they interact. In general
terms, a model’s structure will be determined by the clinical
course of a disease (its “natural history”) and the mode of action
of the alternative interventions.
Again, there may be legitimate differences between jurisdic-
tions in model structure. This is most likely to relate to differ-
ences in the speciﬁed decision problem. If a speciﬁc comparator
is relevant to one jurisdiction but not to another, this may affect
model structure if it needs to reﬂect the particular mode of action
or side effects of the comparator. Similarly, if the relevant patient
population differs between jurisdictions, then the natural history
of the disease may also differ in a way that requires different
structural assumptions.
Parameter estimation. Perhaps the greatest challenge in tailoring
a cost-effectiveness model to the requirements of a particular
jurisdiction relates to parameter estimation; that is, using evi-
dence to estimate the range of inputs necessary for the model. In
many cases, evidence for a model will be sought from a range of
sources—for example, a meta-analysis of clinical trials relating to
the alternative options being evaluated. Nevertheless, evidence is
generated globally, and, at least for some parameter estimates,
the relevance of evidence generated outside of the jurisdiction
of interest is open to doubt. There are numerous studies show-
ing that “economic” measures vary considerably between
jurisdictions—e.g., resource use and unit costs (see Sculpher et al.
[3] for a review). In addition, there are studies showing that a
treatment’s effectiveness can also vary [29].
In addition, it is possible that population health state valua-
tions might vary among jurisdictions, although the evidence on
this is mixed. Jurisdiction-speciﬁc value sets are now available for
some of the generic instruments, such as the EuroQol EQ-5D,
although these have been estimated by using different methods
(e.g., visual analog scale and time trade-off) [30]. Some analysts
argue that differences between the value sets cannot be neglected
and that transferring utility scores across jurisdictions might be
questionable [31–33]. Others argue that, when measurement
methods to derive utilities are truly replicated, there do not seem
to be substantial differences across jurisdictions [34]. Certainly,
in the context of most economic evaluations, the method for
estimating health state valuations is as important as their juris-
diction of origin.
The challenge facing analysts is to be able to estimate
parameters in such a way as to use as much of the evidence as
possible, but to reﬂect variation between jurisdictions. Where
IPD are available, but the jurisdiction of interest did not par-
ticipate in the trial, Manca and Willan [9] argue that the best
approach is to develop an “events-based model,” built around
the generalizable features of the disease or patients’ prognosis
and use the IPD from the trial to estimate the likelihood of
occurrence of the clinical events of interest that are expected to
have an impact on resource use and/or health-related QoL. An
increasingly common approach is to apply the trial-wide rela-
tive risk reduction in the events of interest observed in the trial
(e.g., relative reduction in risk of deaths, myocardial infarction,
adverse effects) to the baseline risk in the jurisdiction of inter-
est, unless there was good reason to believe that the relative
risk reduction from any particular single jurisdiction was more
relevant. Of course, the resource use and costs of the events
and perhaps the values for health states would come from the
jurisdiction of interest. An important challenge in taking
this approach is to locate jurisdiction-speciﬁc baseline risk data.
Furthermore, in some clinical areas (e.g., cardiovascular disease
and osteoporosis), the use of statistical models to predict event
risks as a function of patients’ characteristics is widely used
within cost-effectiveness analyses, but these “risk algorithms”
themselves may be jurisdiction speciﬁc (e.g., the Framingham
Heart Study Cardiovascular risk equations, which were devel-
oped in the United States). In principle, it is possible that these
algorithms may be more generalizable to other jurisdictions
than the data that underlie them because they can be applied to
health-care systems with different patient case-mix. Neverthe-
less, the relevance of the clinical practice reﬂected in the data
used to estimate the algorithms would always need to be
carefully considered, and this will depend on both the health
systems in which the data were collected and the time at which
they were gathered.
A range of approaches has been used in modeling studies as
outlined in Table 1. These include using baseline event risks
from the jurisdiction of interest and a meta-analysis of interna-
tional randomized trials, on the assumption that the latter can
be assumed generalizable; the estimating clinical and economic
parameters for a model using the only trial from the jurisdic-
tion of interest and a secondary analysis where relative treat-
ment effects are based on a meta-analysis of all international
trials; and using data from a multinational trial with regression
modeling to estimate model parameters for the jurisdiction of
interest.
Table 1 Examples of decision modeling studies seeking to inform
decision-making in a particular jurisdiction using evidence from a range of
locations
Henriksson M, Epstein DM, Palmer SJ, Sculpher MJ, Clayton TC, Pocock SJ,
Henderson RA, Buxton MJ, Fox KAA.The cost-effectiveness of an early
interventional strategy in non-ST-elevation acute coronary syndrome
based on the RITA 3 trial. Heart 2008;94:717–723.
This study considered the cost-effectiveness of early intervention (e.g., using
coronary stents) compared with best medical management in patients
with non-ST-elevation acute coronary syndrome. In the primary analysis, it
estimates all clinical, utility and cost parameters using data from the only
trial undertaken in the jurisdiction of interest (the United Kingdom).As a
secondary analysis, it incorporated relative treatment effect data from the
full range of international clinical trials, using a meta-analysis.The advantage
of the primary analysis was that the data are known to relate only the
jurisdiction of interest with no need to “adjust” data from other sources.
Its limitation is that it effectively gives a zero weight to other evidence
that exists outside the jurisdiction of interest.
Briggs AH, Bousquet J,Wallace MV, Busse WW, Clark TJH, Pedersen SE, et al.
Cost-effectiveness of asthma control: an economic appraisal of the GOAL
study. Allergy 2006;61:531.
This study used data from a multinational trial on baseline risks, relative
treatment effects, utility, and resource use data. It used regression methods
using data from the whole trial to estimate costs for the jurisdiction of
interest (United Kingdom). Its strength is that it uses all available data
from clinical trial but models the effect of country of randomization on
costs. However, it assumes all clinical and utility data are fully generalizable
across jurisdictions.
Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai A, et al.
Management of non-ST-elevation acute coronary syndromes: how
cost-effective are glycoprotein IIb/IIIa antagonists in the UK National
Health Service? International Journal of Cardiology 2005;100:229–240.
This analysis used a meta-analysis of relative treatment effects from all trials
regardless of where they were undertaken, baseline risks, resource use,
and utility data from jurisdiction of interest. It assumed that relative
treatment effects were independent of baseline risks but also assessed
the validity of this assumption using meta-regression [10]. However, it still
assumes that relative effects are fully generalizable across jurisdictions and
that resource use and quality of life data are speciﬁc to country of
interest.
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The need for pharmacoeconomics studies is now emerging
in several countries in Central and Eastern Europe, Asia, Latin
America, and Southern Africa. While it is beginning to change,
countries in these regions have not historically been included in
those large (Phase IIIa) multinational trials that collect individual
patient data on resource use or cost. Furthermore, in countries
where the market for pharmaceuticals is small, there is typically
less interest in enrolling patients in Phase IIIb/IV clinical trials. In
such cases, jurisdiction-speciﬁc data on clinical effectiveness of
the new therapy would not be available. To add to the problems,
routine data sources on resource use and costs may not be very
well developed in the jurisdictions concerned.
In this situation, one or other of the approaches outlined
above can be applied. If one or more cost-effectiveness studies
already exist for other jurisdictions, minor adaptations to the
jurisdiction of interest, such as adjusting for local unit costs, may
be possible, based on the approach outlined by Welte et al. [10].
Nevertheless, owing to the differences between the jurisdictions
in these regions and those for which most pharmacoeconomic
studies are conducted (i.e., North America and Western Europe),
it is likely that the general or speciﬁc knockout criteria will apply,
such as the lack of availability of a given comparator therapy or
substantial differences in treatment patterns.
Therefore, it is much more likely that major adaptations
would be necessary (e.g., changing components of the model) or
that a new decision-analytic model would have to be built, as
outlined above. The modeling effort would have to rely on data
published in the literature, for the jurisdiction of interest or other
jurisdictions. Manca and Willan [9] outline the major challenges,
which include relating the model to clinical practice in the juris-
diction of interest, assessing whether the baseline event rates in
the trials conducted elsewhere are relevant to the jurisdiction of
interest, assessing whether the relative risk reductions estimated
from the trials are related to baseline risk, and incorporating
jurisdiction-speciﬁc data on resource use and cost (for a good
example of how these issues can be tackled, see the study by
Palmer et al. [35]).
Whether or not some IPD are available, it is clear that a major
barrier to conducting economic evaluations in some jurisdictions
is the lack of local data. Therefore, to address issues of transfer-
ability, investments need to be made in the collection of epide-
miological and demographic data, plus data on clinical practice
patterns, resource use, costs, and health state valuations.
Smaller jurisdictions with similar health-care systems and
clinical practice patterns (e.g., the Baltic countries) may be able
to develop partnerships to develop relevant regional databases
and registries. Over time, it may be possible to assess whether or
not there are natural groupings of similar jurisdictions, which
may increase our conﬁdence in transferring cost-effectiveness
results from one jurisdiction to another.
Analysis. The ﬁnal stage of decision modeling relates to the use
of the results of the model as a direct input into jurisdiction-
speciﬁc decision-making. It is clear from international methods
guidelines that different jurisdictions require different analytical
methods. For example, some want full probabilistic sensitivity
analysis, whereas some require only one-way sensitivity analysis
[2]. Some of these variations seem reasonable—for example, the
discount rate on future costs and beneﬁts ought to reﬂect local
economic conditions. Nevertheless, many of the other differences
between decision-making agencies in their preferred analytic
methods seem less justiﬁable [36]. These include the principles
for selecting comparators, the choice of health outcome measure,
the principles for determining time horizon, and the methods
for characterizing uncertainty. Nonetheless, for those submitting
analyses to decision-making authorities, their deﬁned analytical
requirements cannot easily be ignored. Nevertheless, the analyst
should always consider supplementing these “required” analyses
with additional ones, including methods that are considered
more scientiﬁcally appropriate.
Trials versus models: the false dichotomy. Largely for presenta-
tional reasons, this article has separated two analytical para-
digms in economic evaluations—analysis of IPD data from
(usually randomized) studies and decision-analytic modeling.
Nevertheless, this is increasingly a false dichotomy, because more
studies effectively use a combination of these methods. Decision-
analytic models are widely used to support decision-making and
provide a powerful framework within which to incorporate a
full range of evidence and to assess the importance of structural
assumptions and particular elements of evidence. Nevertheless,
trials provide key evidence for these models not just on (intended
and unintended) treatment effects but also parameters such as
baseline risk, resource use and health-related QoL. Furthermore,
access to IPD (as opposed to summary results) from trials allows
statistical techniques to be used to provide more suitable param-
eter estimates for models. Advantages of access to IPD for this
purpose include the ability to control for covariates, sub-group
analysis and assessment of time trends in, for example, baseline
risks. The use of meta-analysis based on IPD from several trials
has many advantages including the use of covariate adjustment.
In the context of this article, the methods described in Section 3.2
to analyze potential heterogeneity in cost-effectiveness between
jurisdictions in trials, such as ﬁxed and random effects regression
methods, can also be used in estimating speciﬁc parameters
for decision models (e.g., the costs of particular events). These
methods can be used with data from a single trial or a synthesis
of IPD. An example of where such methods have been used was
described in Table 1.
Conclusions and Recommendations
The work of the Task Force has conﬁrmed that there are several
important methodological and practical issues surrounding the
transferability of economic data. There is some evidence of
the variability in the cost-effectiveness of health technologies
between locations. Also, many international guidelines for
economic evaluation make references to problems concerning
economic data transferability and include requirements for
jurisdiction-speciﬁc data or methods. Against this background,
the Task Force makes the following recommendations.
Developing Guidelines for Economic Evaluation
Those developing guidelines for economic evaluation should
fully justify the need for local data or methods because this
increases the burden on those undertaking studies in multiple
jurisdictions.
Interpreting Existing Studies
Where a study already exists that is relevant to the decision in
the jurisdiction of interest, consideration should be given (using
criteria outlined in this report) to whether it can be used with
simple adaptation (e.g., substituting prices only). Expert opinion
and the existing literature can be used to assess whether the
setting for the study is sufﬁciently similar to the jurisdiction of
interest.
Analysis of IPD from Multinational Studies
Before statistical modeling, simple descriptive statistics should be
used to examine potential differences among jurisdictions in
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incremental costs and effects. Jurisdiction-speciﬁc point esti-
mates, with conﬁdence intervals, should be reported.
Heterogeneity should be explored by using some form
of statistical analysis (e.g., test of interaction, multivariate
regression).
The level of sophistication of the subsequent statistical mod-
eling (i.e., ﬁxed effects vs. random effects) should be guided by
the following criteria: 1) number of jurisdictions (e.g., countries,
clinical centers); 2) exchangeability or nonexchangeability of
data; and 3) the availability of covariates (e.g., at center and
country level). With more jurisdictions, partial exchangeability
of data, and greater availability of covariates, hierarchical mod-
eling is to be preferred.
Addressing Transferability through
Decision-Analytic Models
Analysts should carefully consider which parameters need to be
jurisdiction speciﬁc, wherever possible justifying assumptions
empirically. Current evidence suggests that prices and, in some
instances, baseline risk probably need to be jurisdiction speciﬁc,
whereas treatment effect/relative risk reduction may be more
generalizable. Nevertheless, where possible, this should be dem-
onstrated. The evidence on the generalizability of clinical practice
patterns (resource use) and health state valuations (utilities) is
mixed and, therefore, the use of data from other jurisdictions
needs to be justiﬁed.
If trial-based data are available, analysts should use the
methods typically applied in the analysis of individual patient
data to estimate jurisdiction-speciﬁc model parameters.
Analysts should use scenario analysis (a form of multiway
sensitivity analysis) to explore the implication of different
assumptions about economic data transferability.
Undertaking Further Research into Economic
Data Transferability
More research should be undertaken into those sources of local
differences that affect economic data transferability. This would
help justify jurisdiction-speciﬁc data requirements and inform the
selection of jurisdiction-level covariates in statistical models.
Analysts should evaluate whether certain smaller countries or
other jurisdictions are sufﬁciently similar (in incremental costs
and effects of new health technologies) such that they can
be grouped for the purposes of analysis of economic data
transferability.
Analysts should consider issues of economic data transfer-
ability when designing multinational trials that include economic
data capture. This includes the recruitment of a representative
sample of clinical centers in each jurisdiction and an overall
balance of patient enrolment in the jurisdictions included in the
study. It also includes the collection of data on jurisdiction and
center-level covariates for subsequent statistical modeling.
There should be more investment in data collection for those
parameters that are thought to differ most from place to place.
This would include the establishment of observational studies to
estimate baseline risk and the development of local cost data-
bases (although true of all jurisdictions, this recommendation is
particularly pertinent to smaller countries).
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